Skip to search formSkip to main contentSkip to account menu

lenvatinib 18 MG Daily Dose 30 Day Supply Pack

Known as: LENVATINIB 10MG X 30/4MG X 60 (18MG) DAILY PKT, LENVATINIB 10MG X 5/4MG X 10 (18MG) DAILY PKT [VA Product], LENVATINIB 10MGX5/4MGX10(18MG) DAILY PKT 
National Institutes of Health

Related topics

Related topics

3 relations
PackReceptor Tyrosine Kinase Inhibitors [MoA]lenvatinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States
Introduction Lenvatinib has become the most commonly prescribed first-line (1L) agent for the treatment of radioactive iodine… 
2019
2019
PS-136-Can lenvatinib meet clinical needs of patients with unresectable hepatocellular carcinoma? Multicenter analysis
2019
2019
Mo1454 – Lenvatinib for Patients with Advanced Hepatocellular Carcinoma Refractory to Transcathetal Chemoembolization
2018
2018
Zwei Fälle perforierender Dermatosen bei Therapie mit Multikinase‐Inhibitoren, einer davon assoziiert mit Lenvatinib
2018
2018
Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program
Purpose:Differentiated thyroid cancer (DTC) accounts for approximately 95% of thyroid carcinomas. In the metastatic RAI… 
2018
2018
Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells12
2017
2017
Abstract 1805: Antitumor activity of lenvatinib mesilate in human hepatocellular carcinoma preclinical models
Hepatocellular carcinoma (HCC) is a one of the leading causes of cancer death worldwide; however systemic therapeutic option for… 
2016
2016
Abstract 3262: Effects of lenvatinib mesilate in combination with everolimus on VEGF and FGF-driven angiogenesis and tumor growth
Lenvatinib mesilate (lenvatinib) is an orally available inhibitor for multiple receptor tyrosine kinases (RTKs) that selectively… 
2014
2014
NSCLC: Längeres Überleben bei guter Lebensqualität im Fokus
— Beim fortgeschrittenen nichtkleinzelligen Lungenkarzinom (NSCLC) steht nicht nur die Lebensverlängerung im Fokus, sondern auch… 
2014
2014
新規分子標的薬 lenvatinib (肝細胞癌治療の最前線)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)